Clinical Trial Update: Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of salvage chemotherapy R-ESHAP for relapsed or refractory aggressive Non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CISPLATIN (cisplatin)
• CYTARABINE (CYTARABINE)
• Etoposide (Etoposide)
• METHYLPREDNISOLONE (methylprednisolone)
• Rituximab (rituximab)

Snippet

Sponsor: Keio University | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: TERMINATED